Madam Speaker, it is an honour to be in the House tonight for an adjournment debate with my hon. colleague. I agree with the member that the unfettered marketing of opioids to people in the United States and in Canada has led to extreme amounts of harm. Our government is here to ensure that we achieve accountability with Purdue Pharma.
We are currently working with provinces and territories on the substance use challenge that our country faces. I do understand that the member has a different opinion on how to deal with substance use and addiction. However, we are entitled to our own opinions, but not our own facts.
Substance use harms extend far beyond overdose deaths. The complicated and very multi-faceted nature of substance use harms and the intersection of the overdose crisis with several complex social issues such as mental health, homelessness, experiences of trauma and multi-generational impacts of colonialization means that the most vulnerable people in Canada are the most impacted by this crisis.
That is why we need a comprehensive, integrated and evidence-based response that is grounded on the four internationally recognized pillars of substance use policy, which the member opposite and the Conservative Party do not seem to understand. They are prevention, harm reduction, treatment and enforcement. It is not one or the other, and not one against the other, but all four of those principles.
The toxic drug supply is killing people. People do not know what they are consuming. People fear criminalization, which leads them to use alone and die alone.
In 2018, the Province of British Columbia commenced a proposed class action suit on behalf of all federal, provincial and territorial governments against 50 opioid manufacturers and distributors for allegedly acting inappropriately in the sale and distribution of opioids in Canada.
In addition, British Columbia commenced a separate proposed class action in December 2021 on behalf of all federal, provincial and territorial governments against McKinsey & Company, which allegedly acted inappropriately in the course of providing consulting and advisory services to opioid manufacturers and distributors in relation to marketing and promotion of opioids in Canada.
The Government of Canada supports provinces and territories in their efforts to recover health care costs from any company that acted inappropriately in the marketing and distribution of opioids, and we will be a party to these litigations should they be certified.
I appreciate the interest of the opposition on this issue and his agreeing that it is an important thing to do. The accountability is absolutely necessary but they can see that we are already acting on the issue. I fully invite the member and his party to continue supporting us in ending the crisis instead of continually raising stigma. This litigation is an example of the significant co-operation that exists with provinces and territories as we work together to address the overdose crisis.
That is what this crisis is calling for, co-operation across party lines and across orders of government in collaboration with all of our partners. The health and safety of Canadians is our government's first and top priority. Since the start of this overdose crisis, we have taken significant actions and made commitments of more than $1 billion to respond.
We cannot end this crisis alone. It is our collective obligation and responsibility to work together as parliamentarians with provinces and territories and our community stakeholders to do what they can and what we can to respond to it.
What I would like to know is why the party opposite is continuing to oppose harm reduction. What would the member opposite say to the over 50,000 people whose overdoses have been responded to and reversed? They would otherwise be dead.
Does this party realize that the more than four million visits to safe consumption sites across this country represent four million contacts with a health care provider?
On this side, we want to save lives, not overly stigmatize addiction.